Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
Código da empresaBDSX
Nome da EmpresaBiodesix Inc
Data de listagemOct 28, 2020
CEOMr. Scott Hutton
Número de funcionários273
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 28
Endereço919 West Dillon Road
CidadeLOUISVILLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal80027
Telefone13034170500
Sitehttps://www.biodesix.com/
Código da empresaBDSX
Data de listagemOct 28, 2020
CEOMr. Scott Hutton
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados